Chase Pharma raises $12M for Alzheimer's R&D

Chase Pharmaceuticals, which is helmed by ex-Allergan ($AGN) president Doug Ingram, has raised $12 million, according to a filing with the SEC. The startup is working on a therapy that can be used to allow for higher doses of donepezil in treating Alzheimer's patients. The company has been keeping a low profile so far, and its website is largely a placeholder for what's being planned. Ingram was named CEO back in late 2015. Filing

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i